Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.

Geeta Swamy of Duke University School of Medicine speaks with The Scientist about starting what she considers a long-overdue clinical study of COVID-19 vaccines in pregnant women.

Two out of three people who received noninvasive ultrasound appear to have gained some level of consciousness, according to preliminary trial results.

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.